Voyager Therapeutics reports Q2 EPS (18c), consensus (41c)

Reports Q2 revenue $29.58M, consensus $9.46M. Voyager had collaboration revenue of $29.6M for the second quarter of 2024, compared to $4.9M for the same period in 2023. The increase was primarily due to increased revenue recognized under Neurocrine and Novartis agreements. “Voyager continued to progress our pipeline in the second quarter: we initiated the single ascending dose trial of our anti-tau antibody, which has been shown to substantially reduce the spread of tau in Alzheimer’s disease in vivo models, and enrollment is on track with top-line safety and pharmacokinetic data expected in H1 2025,” said Alfred W. Sandrock, Chief Executive Officer of Voyager. “In parallel, we continued to advance our gene therapy pipeline, and we and our partners are on track to achieve three IND filings in 2025. Our disciplined execution, backed by a strong cash position, should enable us to achieve multiple data readouts during 2025 and 2026.”